Intravitreal Ranibizumabe
PreclinicalSmall molecule
Intravitreal Ranibizumabe is one of 6 small molecule programs targeting Retinopathy. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Retinopathy
#DrugCompanyPhaseTrials
1Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Tricor
JJagotec
Approved
Betadine
BBecton, Dickinson and Company
Approved
Glucophage
EMD SeronoPhase 2
Breast Milk
KKarabuk University
Preclinical
Intravitreal Ranibizumabe
UUniversity of Sao Paulo
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Retinitis Pigmentosa2 trials
Proliferative Diabetic Retinopathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intravitreal Ranibizumabe. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Sao Paulo